Ixekizumab is a humanized monoclonal antibody that inhibits interleukin 17A (IL-17A). It was approved by FDA for the treatment of moderate to severe plaque psoriasis in adult patients.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.